Last €27.38 EUR
Change Today -0.101 / -0.37%
Volume 0.0
SGT On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 3:19 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGT) Snapshot

Open
€28.33
Previous Close
€27.48
Day High
€28.33
Day Low
€27.33
52 Week High
02/26/14 - €40.07
52 Week Low
05/22/14 - €23.79
Market Cap
3.4B
Average Volume 10 Days
20.0
EPS TTM
--
Shares Outstanding
123.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEATTLE GENETICS INC (SGT)

seattle genetics inc (SGT) Related Businessweek News

View More BusinessWeek News

seattle genetics inc (SGT) Details

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. The company is developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Its lead product, ADCETRIS (brentuximab vedotin), is an ADC that has been approved in approximately 35 countries, including the United States, Canada, Japan, and members of the European Union for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in collaboration with Takeda Pharmaceutical Company Limited. The company also evaluates approximately 30 ongoing clinical trials, including Phase III trials for post-transplant HL relapse prevention, relapsed CD30-positive cutaneous T-cell lymphoma, frontline HL in combination with chemotherapy, and frontline CD30-positive mature T-cell lymphoma in combination with chemotherapy, as well as in Phase I and II studies in various lymphoma and non-lymphoma indications. In addition, it is developing a pipeline of other clinical-stage ADC programs, including SGN-CD19A for CD19A-positive hematologic malignancies, SGN-CD33A in CD33-positive acute myeloid leukemia, SGN-LIV1A in LIV-1-positive breast cancer, ASG-22ME for treatment of Nectin-4-positive solid tumors, and ASG-15ME for treatment of SLITRK6-positive bladder cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie, Agensys, Bayer, Genentech, GlaxoSmithKline, and Pfizer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

582 Employees
Last Reported Date: 02/28/14
Founded in 1997

seattle genetics inc (SGT) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $724.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $397.0K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $456.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $383.3K
Executive Vice President of Technical Operati...
Total Annual Compensation: $378.4K
Compensation as of Fiscal Year 2013.

seattle genetics inc (SGT) Key Developments

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

Seattle Genetics Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials. The first trial will evaluate the combination of Adcetris and Opdivo as a potential treatment option for patients with relapsed or refractory Hodgkin lymphoma (HL), and the second trial will focus on patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL). Adcetris is an ADC directed to CD30, a defining marker of classical HL, which combines the targeting ability of a monoclonal antibody with the potency of a cell-killing agent. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T-cells. The studies are expected to begin in 2015, with Seattle Genetics conducting the HL trial and Bristol-Myers Squibb conducting the NHL trial. Additional details of the collaboration were not disclosed.

Seattle Genetics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM

Seattle Genetics Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.

Seattle Genetics Inc. Announces Encouraging Data from Phase I AML Trial

Seattle Genetics Inc. announced data from an ongoing Phase I clinical trial evaluating SGN-CD33A, an antibody-drug conjugate, or ADC, in development for the treatment of acute myeloid leukemia, or AML. SGN-CD33A is a novel ADC targeted to CD33 utilizing Seattle Genetics' newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is the first ADC utilizing an engineered cysteine antibody (EC-mAb) and pyrrolobenzodiazepine (PBD) dimer to be advanced into the clinic.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGT:GR €27.38 EUR -0.101

SGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $6.45 USD +0.01
Genmab A/S kr442.80 DKK +1.50
Insys Therapeutics Inc $47.78 USD -1.73
MorphoSys AG €76.10 EUR -0.30
Pfizer Ltd/India 2,047 INR 0.00
View Industry Companies
 

Industry Analysis

SGT

Industry Average

Valuation SGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.8x
Price/Book 17.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.